ArticleMolecular psychiatry2026
Overactive Neuronal eEF2K/eEF2 signaling is associated with cognitive impairment and apathy-like behavior.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Suppression of neuronal p27 impairs cognitive function in middle-aged mice.Neurobiology of disease · 2026Article
- Synaptic Potentiation in Hippocampus by eEF2K Inhibitor A484954.Hippocampus · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Dysregulated protein synthesis has been implicated in multiple neurodevelopmental, neurodegenerative, and neuropsychiatric diseases. Protein synthesis or mRNA translation is critically regulated through phosphorylation of eukaryotic elongation factor 2 (eEF2) by its kinase eEF2K. Increased eEF2K activity leads to elevated phosphorylation and inhibition of eEF2 and inhibits the elongation phase of protein synthesis. Recent studies suggest a link between eEF2 hyper-phosphorylation and several neuronal diseases characterized by cognitive impairments. Phosphorylation of eEF2 by eEF2K has also been implicated as a molecular mechanism for the rapid antidepressant effect of ketamine. Whether there exists a causal relationship between overactive eEF2K/eEF2 signaling and impaired synaptic and cognitive function remains unknown. To fill this critical knowledge gap, we generated a transgenic mouse model (eEF2K-cKI) overexpressing eEF2K in excitatory neurons to investigate how eEF2K/eEF2 signaling can impact cognitive functions and neuropsychiatric behaviors. We assessed hippocampal-dependent learning and memory, as well as multiple neuropsychiatric domains associated with a depressive phenotype including despair, anhedonia, apathy, anxiety, and sociability. The eEF2K-cKI mice exhibit learning and memory impairments, and robust apathy-like phenotype without other despair/depression-like behaviors. We also found impaired long-term potentiation and altered dendritic spine and synaptic morphology in the hippocampus of the eEF2K-cKI mice. Proteomic analysis revealed changes in levels of proteins associated with neuropsychiatric and neurodegenerative disorders. Our findings present direct evidence supporting the pathophysiological role of aberrant eEF2K/eEF2 signaling in brain function and help provide insight into novel mechanisms and therapeutic avenues for neuronal diseases characterized by dementia and neuropsychiatric symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.